Financial Comparison
ELI Lilly And Company vs Merck & Co., Inc.
Click a ticker to view the full analysis.
In short
ELI Lilly And Company is the more profitable of the two, keeping 31.7% of revenue as net profit against 28.1% for Merck & Co., Inc. Merck & Co., Inc. trades at the higher trailing P/E (113.0× vs 39.9× for ELI Lilly And Company), so investors pay more for each dollar of its earnings. Fisclear flags 0 medium- or high-severity risks for ELI Lilly And Company and 1 for Merck & Co., Inc.
Based on filings for periods ending 30 Jun 2026 (LLY) and 30 Jun 2026 (MRK) · Updated
FisclearScore Comparison
FisclearScore is a quantitative model. LLY shown solid · MRK shown dashed. Not financial advice.
| Metric | LLY | MRK |
|---|---|---|
| Price | $1,169.60 | $142.38 |
| Market Cap | $1.04T | $351.3B |
| P/E (TTM) | 39.9x | 113.0x |
| P/B | 30.8x | 8.4x |
| Beta | 0.45 | 0.22 |
| Div Yield | 0.59% | 2.34% |
| Revenue (TTM) | $65.2B | $65.0B |
| Net Income | $20.6B | $18.3B |
| Gross Margin | — | — |
| Risk Flags | — | 1 flag |
Related comparisons
Data sourced from SEC EDGAR, Yahoo Finance, and official exchange filings. For informational purposes only. Not financial advice.